The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
The untapped potential of ascites in ovarian cancer research and treatment
Open accessAbstract
The build-up of fluid in the peritoneal cavity-ascites-is a hallmark of ovarian cancer, the most lethal of all gynaecological malignancies. This remarkable fluid, which contains a variety of cellular and acellular components, is known to contribute to patient morbidity and mortality by facilitating metastasis and contributing to chemoresistance, but remains largely under-researched. In this review, we will critically analyse the evidence associating ascites with metastasis and chemoresistance in ovarian cancer and provide an update on research in the field. We will argue the case for ascites as a unique and accessible substrate for tracking tumour progression and for translational research that will enhance our understanding of this cancer and lead to improvements in patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They disseminate by forming aggregates of multicellular spheroids that float in malignant ascitic fluid alongside fibroblasts, adipocytes, mesothelial, endothelial and inflammatory cells, as well as cell-free DNA, before “seeding” onto new microenvironments and establishing metastatic deposits (Ford et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Ford et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M. W., Reinhard, F., Zhang, C. C., Shipitsin, M. V., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,839
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I. B., Trope, C. G., Amant, F. C., Kristensen, G. B., Ehlen, T., Johnson, N. P., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, Á. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,538
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H. Q., Mannel, R. S., Homesley, H. D., Fowler, J. M., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,413
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, É., Kristensen, G. B., Carey, M. S., Beale, P. J., Cervantes, A. M. R., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,181
Ovarian Cancer Development and Metastasis
Lengyel, E. R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,702
Pujade-Lauraine, É., Hilpert, F., Weber, B. E., Reuß, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P. O., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,660
Cited by
Sorted by citations
Rickard, B. P., Conrad, C., Sorrin, A. J., Ruhi, M. K., Reader, J. C., Huang, S. A., Franco, W., Scarcelli, G., Polacheck, W. J., Roque, D. M., et al. (2021) · Cancers · doi:10.3390/cancers13174318 · Cited by 163
Luo, Y., Xia, Y., Liu, D., Li, X., Li, H., Liu, J., Zhou, D., Dong, Y. J., Li, X., Qian, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.013 · Cited by 120
Tumor microenvironment in ovarian cancer peritoneal metastasis
Mei, S., Chen, X., Wang, K., & Chen, Y. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02854-5 · Cited by 112
Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers
Wenk, D., Zuo, C., Kislinger, T., & Sepiashvili, L. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09452-1 · Cited by 112
TGFβ signaling networks in ovarian cancer progression and plasticity
Kumari, A., Shonibare, Z., Monavarian, M., Arend, R. C., Lee, N. Y., Inman, G. J., & Mythreye, K. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10077-z · Cited by 78
Wang, W., Jo, H., Park, S., Kim, H., Kim, S. I., Han, Y., Lee, J., Seol, A., Kim, J., Lee, M., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215735 · Cited by 67
Biology-driven therapy advances in high-grade serous ovarian cancer
Wang, Y., Duval, A. J., Adli, M., & Matei, D. E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174013 · Cited by 74
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
Neutrophil interactions with T cells, platelets, endothelial cells, and of course tumor cells
Segal, B. H., Giridharan, T., Suzuki, S., Khan, A. N. H., Zsíros, E., Emmons, T. R., Yaffe, M. B., Gankema, A. A. F., Hoogeboom, M., Goetschalckx, I., et al. (2022) · Immunological Reviews · doi:10.1111/imr.13178 · Cited by 67
Carvalho, R. F., do Canto, L. M., Abildgaard, C., Aagaard, M. M., Tronhjem, M. S., Waldstrøm, M., Jensen, L. H., Steffensen, K. D., & Rogatto, S. R. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00991-4 · Cited by 54
Yokoi, A., Yoshida, K., Koga, H., Kitagawa, M., Nagao, Y., Iida, M., Kawaguchi, S., Zhang, M., Nakayama, J., Yamamoto, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42593-9 · Cited by 51
Frisbie, L. G., Pressimone, C. A., Dyer, E., Baruwal, R., Garcia, G. L., Croix, C. M. S., Watkins, S. C., Calderone, M., Gorecki, G., Javed, Z., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114551 · Cited by 50
Tarannum, M., Dinh, K., Vergara, J. A., Birch, G. C., Abdulhamid, Y. Z., Kaplan, I. E., Ay, O., Maia, A., Beaver, O., Sheffer, M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn0881 · Cited by 48
Rakina, M. A., Казакова, А., Виллерт, А. Б., Коломиец, Л. А., & Larionova, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116215 · Cited by 48
Tomás-Pérez, S., Oto, J., Aghababyan, C., Herranz, R., Cuadros-Lozano, A., González-Cantó, E., Cormack, B. A. M., Arrés, J., Castaño, M., Cana, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111344 · Cited by 45
Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective
Qian, L., Sun, R., Xue, Z., & Guo, T. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100578 · Cited by 46
Castaño, M., Tomás-Pérez, S., González-Cantó, E., Aghababyan, C., Mascarós-Martínez, A., Santonja, N., Herreros‐Pomares, A., Oto, J., Medina, P., Götte, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065995 · Cited by 43
The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models
Tadić, V., Zhang, W., & Brozović, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189052 · Cited by 43
Capellero, S., Erriquez, J., Battistini, C., Porporato, R., Scotto, G., Borella, F., Renzo, M. F. D., Valabrega, G., & Olivero, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020833 · Cited by 42
Casagrande, N., Borghese, C., Agostini, F., Durante, C., Mazzucato, M., Colombatti, A., & Aldinucci, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063019 · Cited by 41
Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer
Werner, B., Yuwono, N. L., Duggan, J., Liu, D., David, C., Srirangan, S., Provan, P. J., DeFazio, A., Arora, V., Farrell, R., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.06.028 · Cited by 40
Ye, Z., Xu, S., Shi, Y. P., Cheng, X., Zhang, Y., Roy, S., Namjoshi, S., Longo, M. A., Link, T. M., Schlacher, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46283-y · Cited by 39
Circulating Proteins as Diagnostic Markers in Gastric Cancer
Repetto, O., Vettori, R., Steffan, A., Cannizzaro, R., & Re, V. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316931 · Cited by 38
Uno, K., Iyoshi, S., Yoshihara, M., Kitami, K., Mogi, K., Fujimoto, H., Sugiyama, M., Koya, Y., Yamakita, Y., Nawa, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084383 · Cited by 36
Qi, L., Chen, D., Li, C., Li, J., Wang, J., Zhang, C., Li, X., Qiao, G., Wu, H., Zhang, X., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.753948 · Cited by 33
Kim, S., Han, Y., Kim, S. I., Lee, J., Jo, H., Wang, W., Cho, U., Park, W., Rando, T. A., Dhanasekaran, D. N., et al. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23289 · Cited by 32
Rickard, B. P., Tan, X. M., Fenton, S. E., & Rizvi, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095176 · Cited by 34
Bortot, B., Apollonio, M., Rampazzo, E., Valle, F., Brucale, M., Ridolfi, A., Ura, B., Addobbati, R., Lorenzo, G. D., Romano, F., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13110 · Cited by 33
Kotrbova, A. V., Gömöryová, K., Mikulová, A., Plešingerová, H., Sladeček, S., Kravec, M., Hrachovinová, Š., Potěšil, D., Dunsmore, G., Blériot, C., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12420 · Cited by 32
Li, Y., Hu, Y., Yang, L., Liu, J., Cui, C., Yang, M., Zou, D., Zhou, L., Zhou, Q., Ge, W., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114350 · Cited by 31
Wang, H., Yung, M. M. H., Yang, X., Chen, F., Chan, W., Siu, M. K. Y., Long, R., Jia, S., Liang, Y., Xu, D., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00558-8 · Cited by 32
Luo, H., She, X., Zhang, Y., Xie, B., Zhang, S., Li, Q., Zhou, Y., Guo, S., Zhang, S., Jiang, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202411314 · Cited by 31
Multicellular ovarian cancer spheroids: novel 3D model to mimic tumour complexity
Flörkemeier, I., Antons, L. K., Weimer, J. P., Hedemann, N., Rogmans, C., Krüger, S., Scherließ, R., Dempfle, A., Arnold, N., Maass, N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-73680-6 · Cited by 35
Han, L., Xu, S., Zhou, D., Chen, R., Ding, Y., Zhang, M., Bao, M., He, B., & Li, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1401648 · Cited by 29
Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells
Tonetti, C. R., de Souza-Araújo, C. N., Yoshida, A., da Silva, R. F., Alves, P. C. M., Mazzola, T. N., Derchain, S., Fernandes, L. G. R., & Guimarães, F. (2021) · Cells · doi:10.3390/cells10071702 · Cited by 29
Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Sandoval, T. A., Salvagno, C., Chae, C.-S., Awasthi, D., Giovanelli, P., Falco, M. M., Hwang, S., Terán-Cabanillas, E., Suominen, L., Yamazaki, T., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1451 · Cited by 29
Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment
Hilliard, T. S., Kowalski, B., Iwamoto, K., Agadi, E., Liu, Y., Yang, J., Asem, M., Klymenko, Y., Johnson, J. J., Shi, Z., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212443 · Cited by 27
Targeting Aquaporins in Novel Therapies for Male and Female Breast and Reproductive Cancers
Khan, S., Ricciardelli, C., & Yool, A. J. (2021) · Cells · doi:10.3390/cells10020215 · Cited by 25
Teng, K., Ford, M. J., Harwalkar, K., Li, Y., Pacis, A., Farnell, D., Yamanaka, N., Wang, Y.-C., Badescu, D., Nu, T. N. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1518 · Cited by 26
Zhao, Z., Xu, H., Wei, Y., Sun, L., & Song, Y. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166594 · Cited by 25
Zhang, J., Yin, Z., Liang, Z., Bai, Y., Zhang, T., Yang, J., Li, X., & Xue, L. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0136 · Cited by 24
Monavarian, M., Elhaw, A. T., Tang, P. W., Javed, Z., Shonibare, Z., Scalise, C. B., Arend, R. C., Jolly, M. K., Sewell-Loftin, M. K., Hempel, N., et al. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.004 · Cited by 24
Aquino-Acevedo, A. N., Knochenhauer, H. E., Castillo-Ocampo, Y., Ortiz-León, M., Rivera-López, Y. A., Morales-López, C., Cruz-Robles, M. E., Hernández-Cordero, E. R., Russell, S., Whitaker, R. S., et al. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100558 · Cited by 25
Hugendieck, G., Lettau, M., Andreas, S., Neumann, S., Reinhardt, N., Arnold, P., Theilig, F., Bastian, L., Rogmans, C., Weimer, J. P., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12338 · Cited by 23
Transcending Blood—Opportunities for Alternate Liquid Biopsies in Oncology
Werner, B., Warton, K., & Ford, C. E. (2022) · Cancers · doi:10.3390/cancers14051309 · Cited by 23
Sphingolipids as multifaceted mediators in ovarian cancer
Pitman, M. R., Oehler, M. K., & Pitson, S. M. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.109949 · Cited by 21
Casagrande, N., Borghese, C., Gabbatore, L., Morbiato, L., Zotti, M. D., & Aldinucci, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168362 · Cited by 21
Metabolic Reprogramming of Ovarian Cancer Spheroids during Adhesion
Compton, S. L. E., Grieco, J. P., Gollamudi, B., Bae, E., Mullekom, J. H. V., & Schmelz, E. M. (2022) · Cancers · doi:10.3390/cancers14061399 · Cited by 20
Miyazaki, M., Nakabo, A., Nagano, Y., Nagamura, Y., Yanagihara, K., Ohki, R., Nakamura, Y., Fukami, K., Kawamoto, J., Umayahara, K., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215983 · Cited by 20
Nunes, M., Duarte, D., Vale, N., & Ricardo, S. A. V. (2022) · Cancers · doi:10.3390/cancers14184357 · Cited by 19
In Vitro Models of Ovarian Cancer: Bridging the Gap between Pathophysiology and Mechanistic Models
Lopez, E., Kamboj, S., Chen, C., Wang, Z., Kellouche, S., Leroy‐Dudal, J., Carreiras, F., Lambert, A., & Aimé, C. (2023) · Biomolecules · doi:10.3390/biom13010103 · Cited by 23
Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells
Carmi, Y. K., Agbarya, A., Khamaisi, H., Farah, R. E., Shechtman, Y., Korobochka, R., Gopas, J., & Mahajna, J. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101939 · Cited by 21
Li, C., Men, C., Yang, W., Chen, R., Zhu, J., & Cheng, Z. (2023) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12652 · Cited by 18
Yamaguchi, H., & Miyazaki, M. (2025) · Cancer Science · doi:10.1111/cas.70021 · Cited by 19
Athira, M., Lekshmi, G. S., Rajeev, M. R., & Anirudhan, T. S. (2025) · Journal of environmental chemical engineering · doi:10.1016/j.jece.2025.116239 · Cited by 18
Circular RNAs in Epithelial Ovarian Cancer: From Biomarkers to Therapeutic Targets
Qiu, Y., Chen, Y., Agbede, O., Eshaghi, E., & Peng, C. (2022) · Cancers · doi:10.3390/cancers14225711 · Cited by 19
Silva, R., Glennon, K., Metoudi, M., Moran, B., Salta, S., Slattery, K., Treacy, A. D., Martin, T., Shaw, J., Doran, P., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34496 · Cited by 18
Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer
Chen, M., Li, Y., Wu, Y., Xie, S., Ma, J., Yue, J., Lv, R., Tian, Z., Fang, F., & Xiao, W. (2021) · Cancers · doi:10.3390/cancers13225866 · Cited by 18
The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance
Grillo, E., Romani, C., Ettorre, V. M., Santin, A. D., & Mitola, S. M. F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189374 · Cited by 19
Malignant ascites in ovarian cancer: New advances and translational opportunities
Boo, K. H., Lee, G., & Song, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102568 · Cited by 17
Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC
Arend, R. C., Scalise, C. B., Gordon, E. R., Davis, A. M., Foxall, M. E., Johnston, B. E., Crossman, D. K., & Cooper, S. J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2984 · Cited by 17
Limitations and potential of immunotherapy in ovarian cancer
Kumar, S., Acharya, S., Karthikeyan, M., Biswas, P., & Kumari, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292166 · Cited by 18
A Recipe for Successful Metastasis: Transition and Migratory Modes of Ovarian Cancer Cells
Śliwa, A., Szczerba, A., Pięta, P., Białas, P., Lorek, J., Nowak‐Markwitz, E., & Jankowska, A. (2024) · Cancers · doi:10.3390/cancers16040783 · Cited by 17
Zhang, J., He, T., Yin, Z., Shang, C., Xue, L., & Guo, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.864021 · Cited by 20
Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis
Hendrikson, J., Liu, Y., Ng, W. H., Lee, J. Y., Lim, A. H., Loh, J. W., Ng, C. C. Y., Ong, W. S., Tan, J. W., Tan, Q. X., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100526 · Cited by 16
Friend and foe: the regulation network of ascites components in ovarian cancer progression
Geng, Z., Pan, X., Xu, J., & Jia, X. (2022) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-022-00698-8 · Cited by 15
Gendrau‐Sanclemente, N., Figueras, A., Gracova, K., Lahiguera, Á., Alsina‐Sanchís, E., Marín‐Jiménez, J. A., Vidal, A., Matías‐Guiu, X., Fernández-González, S., Barahona, M., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13556 · Cited by 15
Zheng, C., Niu, G., Tan, H., Huang, X., Lu, J., Mai, Q., Yu., T. S., Zhang, C., Chen, S., Wei, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58525-8 · Cited by 15
Thorel, L., Dolivet, É., Morice, P., Florent, R., Divoux, J., Perréard, M., Lecouflet, L., Desmartin, G., Alagama, C. M., Giffard, F., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03537-x · Cited by 14
Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics
Dogra, S., Adhikari, L., Benbrook, D. M., Bohn, J. A., Burgett, A. W. G., Chandra, V., Dockery, L., Singh, A., McNally, L. R., Rai, R., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02438-z · Cited by 14
Nasioudis, D., Byrne, M. E., Ko, E. M., Haggerty, A. F., Cory, L. A., Giuntoli, R. L., Kim, S. H., & Latif, N. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-002978 · Cited by 14
Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins
Almeida-Nunes, D. L., Silvestre, R., Dinis‐Oliveira, R. J., & Ricardo, S. A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010323 · Cited by 14
Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization
Chung, D. C., Garcia-Batres, C. R., Millar, D. G., Wong, S. W., Elford, A. R., Mathews, J. A., Wang, B. X., Nguyen, L. T., Shaw, P. A., Clarke, B. A., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300834 · Cited by 16
Thorel, L., Divoux, J., Lequesne, J., Babin, G., Morice, P., Florent, R., Desmartin, G., Lecouflet, L., Alagama, C. M., Leconte, A., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12429-w · Cited by 14
Cardiac Atrophy, Dysfunction, and Metabolic Impairments
Ogilvie, L. M., Delfinis, L. J., Coyle‐Asbil, B., Vudatha, V., Alshamali, R., Garlisi, B., Pereira, M., Matuszewska, K., Garibotti, M. C., Gandhi, S., et al. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.06.008 · Cited by 14
Shi, G., Shi, P., Yu, Y., Xu, J. X., Ma, J., Zhang, Y., Dong, Z., Shen, L., Dai, L., Cheng, L., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.008 · Cited by 15
Cortesi, M., Liu, D., Yee, C., Marsh, D. J., & Ford, C. E. (2023) · Scientific Reports · doi:10.1038/s41598-023-42486-3 · Cited by 13
Progress in the treatment of malignant ascites
Wang, Y., Sun, Y., Li, X., Yu, X., Zhang, K., Liu, J., Tian, Q., Zhang, H., Du, X., & Wang, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104237 · Cited by 15
A nomogram model based on clinical markers for predicting malignancy of ovarian tumors
Gao, B., Zhao, X., Gu, P., Sun, D., Liu, X., Li, W., Zhang, A., Peng, E., & Xu, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.963559 · Cited by 13
Nelson, L., Barnes, B. M., Tighe, A., Littler, S., Coulson‐Gilmer, C., Golder, A., Desai, S. N., Morgan, R. D., McGrail, J. C., & Taylor, S. S. (2023) · Chromosome Research · doi:10.1007/s10577-023-09731-x · Cited by 13
The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers
Henderson, E. C., Huynh, G. T., Wilson, K., Plebanski, M., & Corrie, S. R. (2021) · Biomedicines · doi:10.3390/biomedicines9111554 · Cited by 14
Nunes, M., Duarte, D., Vale, N., & Ricardo, S. A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010097 · Cited by 12
Li, J., Faruque, H. A., Li, S., Sima, M., Sborov, D. W., Hu‐Lieskovan, S., Werner, T. L., Kopeček, J., & Yang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113682 · Cited by 12
Yu, J., Che, L., Zhu, A., Xu, L., & Huang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.833273 · Cited by 12
Pampeno, C., Opp, S., Hurtado, A. M., & Meruelo, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052925 · Cited by 11
Romaniuk-Drapała, A., Skupin-Mrugalska, P., Garbuzenko, O. B., Hatefi, A., & Minko, T. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03469-0 · Cited by 11
Ovarian cancer extracellular vesicle biomarkers
Jamali, Z., Razipour, M., Zargar, M., Ghasemnejad‐Berenji, H., & Akrami, S. M. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.120011 · Cited by 11
Advanced Therapeutic Approaches for Metastatic Ovarian Cancer
Choe, S., Jeon, M., & Yoon, H. (2025) · Cancers · doi:10.3390/cancers17050788 · Cited by 11
Lupia, M., Melocchi, V., Bizzaro, F., Riso, P. L., Dama, E., Baronio, M., Ranghiero, A., Barberis, M. C. P., Bernard, L., Bertalot, G., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33983 · Cited by 11
Li, Y., Wang, W., Wang, D., Zhang, L., Wang, X., He, J., Cao, L., Li, K., & Xie, H. (2022) · Genes · doi:10.3390/genes13122276 · Cited by 11
Mulchandani, V., Banerjee, A., Vadlamannati, A. V., Kumar, S., & Sarma, J. D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114296 · Cited by 11
A single-cell landscape of pre- and post-menopausal high-grade serous ovarian cancer ascites
Chen, W., Liu, H., Huang, X., Qian, L., Chen, L., Yong-gang, Z., Liu, Y., Liu, Y., Wang, Y., Zhang, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107712 · Cited by 12
Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression
Almeida-Nunes, D. L., Nunes, M., Osório, H., Ferreira, V., Lobo, C., Monteiro, P., Abreu, M. H., Bartosch, C., Silvestre, R., Dinis‐Oliveira, R. J., et al. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101755 · Cited by 10
Deng, S., Kim, W., Cheng, K., Yang, Q., Singh, Y., Bae, G., Bézière, N., Mager, L. F., Kommoss, S., Sprengel, J., et al. (2025) · Cancer & Metabolism · doi:10.1186/s40170-025-00391-5 · Cited by 10
Insights into the tumor-stromal-immune cell metabolism cross talk in ovarian cancer
Tang, P. W., Frisbie, L. G., Hempel, N., & Coffman, L. G. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00588.2022 · Cited by 10
Luo, N., Sulaiman, Z., Wang, C., Ding, J., Chen, Y., Liu, B., Cheng, Z., & Liu, S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03404-9 · Cited by 10
Chen, K., Zhai, Y., Wang, Y., Xu, Z., Chen, X., Zhang, Y., Zhou, Z., Zheng, X., & Lin, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117110 · Cited by 9
Zhou, S., Xu, J., Gao, X.-Q., Zhang, R., Cheng, F.-F., Yao, W.-F., Zhang, Y., Geng, T., & Zhang, L. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155895 · Cited by 9
Liu, Y., Xiao, H., Zeng, H., & Xiang, Y. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5705 · Cited by 10
Extracellular vesicles display distinct glycosignatures in high-grade serous ovarian carcinoma
Bienes, K. M., Yokoi, A., Kitagawa, M., Kajiyama, H., Thaysen‐Andersen, M., & Kawahara, R. (2025) · BBA Advances · doi:10.1016/j.bbadva.2025.100140 · Cited by 9
Metadata
- Authors
- Ford, C. E., Werner, B., Hacker, N. F., & Warton, K.
- Affiliations
- UNSW Sydney (AU)
- Corresponding author
- Ford, Caroline Elizabeth
- Venue
- British Journal of Cancer
- Published
- 2020-05-08
- Volume
- 123
- Issue
- 1
- Pages
- 9-16
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC7341795
- OpenAlex
- W3022087601
- Cited by
- 261
- References
- 110
- Citations by year
- 2026: 44 · 2025: 51 · 2024: 60 · 2023: 46 · 2022: 42 · 2021: 18
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- British Journal of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Translational Cancer Research Network
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- ascites, ovarian cancer, peritoneal carcinomatosis, chemoresistance, translational research
- MeSH terms
- Ascites, Female, Humans, Ovarian Neoplasms, Ovary, Biomarkers, Tumor, Proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
